Advertisement

Topics

Kiadis gains NK-cell technology for immunology therapies through CytoSen acquisition

11:14 EDT 17 Apr 2019 | BioPharma-Reporter

Kiadis Pharma acquires CytoSen Therapeutics and gains NK-cell technology capabilities to complement its own T-cell platform.

Original Article: Kiadis gains NK-cell technology for immunology therapies through CytoSen acquisition

NEXT ARTICLE

More From BioPortfolio on "Kiadis gains NK-cell technology for immunology therapies through CytoSen acquisition"

Advertisement
Quick Search
Advertisement
Advertisement